The use of ascorbyl palmitate as vaccine platform does not modify the immune response under different storage conditions.

FEDERICO N. RUIZ MORENO; CONSTANZA MARIN; GIULIANA, VEDELAGO; ALLEMANDI DANIEL A; PALMA, SANTIAGO D; MARÍA C. PISTORESI; MORÓN, VICTOR G; BELKYS A. MALETTO

Congreso; Reunión anual de sociedades de biociencias SAIC, SAI, FAIC, SAFIS 2022; 2022

Previously we demonstrated that the nanoformulation of OVA and CpG-ODN with a nanostructure formed by self-assembly of 6-O-ascorbyl palmitate (Coa-ASC16) elicited antigen-specific antibody and cellular responses superior to those induced by the soluble counterpart. Here, we study the stability of the nanoformulation OVA/CpG-ODN/Coa-ASC16 keeping it for 2 days at room temperature and for 30 days at 4°C, using the newly prepared nanoformulation as a control. Mice were subcutaneously immunized with a single dose of OVA and CpG-ODN nanoformulated with Coa-ASC16 (OVA/CpG-ODN/Coa-ASC16) maintained under the different storage conditions. Then, we evaluate the SIINFEKL-Kb tetramer+ CD8+ T cells, OVA-specific antibody response and INFɣ produced by spleen cells upon rechallenge in vitro with OVA. ELISA and flow cytometry techniques were used. The results reveal that the OVA-specific antibody and cellular responses elicited were similar among the three groups of mice regardless of the formulation used (p:NS). These data showed that the ambient temperature as well as the conservation short time of the nanoformulation does not produce changes on immune response elicited, an indicator of its biological function.